Phase 1/2 Study to Evaluate the Safety and Efficacy of ATA188 in Subjects With Progressive
Multiple Sclerosis
Research Question:
Is ATA188 effective as a therapy for those with progressive multiple sclerosis?
Basic Study Information
Purpose:
The purpose of this study is to evaluate the safety and tolerability of ATA188 as
a
monotherapy in Parts 1 and 2, to determine the recommended Part 2 dose (RP2D) of ATA188
as
monotherapy in Part 1, and to evaluate the effect of ATA188 treatment on clinical
disability,
as assessed by sustained Expanded Disability Status Scale (EDSS) improvement at 12
months in
Part 2 in participants with progressive forms of multiple sclerosis (MS) (primary
progressive
multiple sclerosis [PPMS] and secondary progressive multiple sclerosis [SPMS]).
Location: University of Rochester Medical Center
Study Reference #: 00005559
Lead Researcher (Principal Investigator)
Lead Researcher:
Andrew Goodman
Study Contact Information
Study Coordinator: Jennifer Voelkl
Phone: (585) 276-3513
Email: JenniferM_Voelkl@URMC.Rochester.edu
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search